Abstract:OBJECTIVE To fuse human hepatocellular carcinoma (HCC) cells with mature monocyte-derived dendritic cells (FastDC) and to observe in vitro the function of the fused cells in stimulating autologous T cells proliferation and inducing HCC-specific cytotoxic T lymphocyte (CTL) response. METHODS CD14(+) cells were isolated and purified from the peripheral blood of a healthy HLA-A2 blood donor and cultured in fresh dendritic cell complete medium for 24 h, then proinflammatory mediators were supplemented for another 24 h, thus generating mature dendritic cell (FastDCs). The FastDCs were fused with human HCC cells of the line HCCLM3 to generate novel dendritoma. T cells were isolated from selected CD14(-) cells and then divided into 4 groups to be stimulated with dendritoma cells, DCs, HCCLM3 cells, and mixed DCs-HCCLM3 cells respectively for 96 hours. 18 hours before the end of cultivation (3)H-TdR was added into the culture fluid. Scintillation counter was used to measure the cpm values. CD8(+)T cells were isolated from CD14(-) cells, and added with different stimulating cells radiated by (60)Co and IL-2, IL-6, and IL-7. The values of IFN-gamma in the supernatants of the culture fluid of CD8(+)T cells with dendritoma cells, DCs, HCCLM3 cells, and mixed DCs-HCCLM3 cells was measured. HCCLM3, K562, HLE, self monocytes labeled with Na(2)(51)CrO(4) were added with effector cells, gamma-scintillation counter was used to measure the cpm value so as to calculate the killing ability of CTL. RESULTS The CTLs activated by dendritoma cells specifically killed the HCCLM3 cells in the context of MHC class I and acted less vigorously against the control target cells. The CTLs activated by dendritoma cells were stronger in killing HCCLM3 cells than DCs, HCCLM3 cells, and mixed DCs-HCCLM3 cells (all P < 0.05). The killing activity was decreased on the HCCLM3 cells incubated with anti-HLA-ABC antibody. Three, five, and seven days after co-cultivation the value of IFN-gamma in the supernatants of the culture fluid of CD8(+)T cells with fused cells, DCs, HCCLM3 cells, and mixed DCs-HCCLM3 cells increased gradually, especially in the supernatants of the culture fluid of CD8(+)T cells with dendritoma cells (400 pg/ml +/- 60 pg/ml 3 days after, 1030 pg/ml +/- 160 pg/ml 5 days after, and 1260 pg/L +/- 180 pg/L 7 days after). CONCLUSION The novel dendritomas formed with HCCLM3 cells and mature FastDCs from healthy human peripheral blood CD14(+) monocytes are potent stimulators for CD8(+)T cells in inducing HCCLM3 cell-specific lysis. With shorter time required for in vitro DC development, the rapid method of generation of dendritoma is more economic and may represent a new strategy for immunotherapy of hepatocellular carcinoma.

Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells.

B-106 Development of Anti-Tumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

P3.02c-049 Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrate Enhanced Antitumor Effect Against Lung Cancer

Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer

Induction of Specific Cytolytic T Lymphocytes Using Fusions of Hepatocellular Carcinoma (HCC) Patient-Derived Dendritic Cells and Allogeneic HCC Cell Line.

Antitumor Effect of Lung Cancer Vaccine with Umbilical Blood Dendritic Cells in Reconstituted Scid Mice

Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy

Enhanced Human T Lymphocyte Antigen Priming by Cytokine-Matured Dendritic Cells Overexpressing Bcl-2 and IL-12.

Human Induced-T-to-natural Killer Cells Have Potent Anti-Tumour Activities.

Superior Anti-Tumor Protection and Therapeutic Efficacy of Vaccination with Dendritic Cell/Tumor Cell Fusion Hybrids for Murine Lewis Lung Carcinoma

Eliciting Cytotoxic T Lymphocytes Against Human Laryngeal Cancer-Derived Antigens: Evaluation of Dendritic Cells Pulsed with a Heat-Treated Tumor Lysate and Other Antigen-Loading Strategies for Dendritic-Cell-based Vaccination

In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirus.

[Inducing Hepatocellular Carcinoma-Specific Cytotoxic T Lymphocyte Response Using Formed by Fusion of FastDCs and Allogeneic Human Hepatocellular Carcinoma Cells].

Skin-Grafting and Dendritic Cell "Boosted" Humanized Mouse Models Allow the Pre-Clinical Evaluation of Therapeutic Cancer Vaccines

Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer

Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.

A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dentritomas

Antitumor Activity from Antigen-Specific CD8 T Cells Generated in Vivo from Genetically Engineered Human Hematopoietic Stem Cells

A Hybrid of B and T Lymphoblastic Cell Line Could Potentially Substitute Dendritic Cells to Efficiently Expand out Her-2/neu-specific Cytotoxic T Lymphocytes from Advanced Breast Cancer Patients in Vitro